Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Phase 2 Trial to Evaluate the Safety, Tolerability and Efficacy of CPI-613 in Cancer Patients

NCT01832857 is registered in ClinicalTrials.gov with Cornerstone Pharmaceuticals as lead sponsor.

NCT NCT01832857
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01832857 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Phase 2 Trial to Evaluate the Safety, Tolerability and Efficacy of CPI-613 in Cancer Patients
Lead sponsor
Cornerstone Pharmaceuticals
Phase
Phase 2
Overall status
Terminated
Start date
June 30, 2013
Completion date
December 31, 2016
Enrollment
7 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cancer